RÉSUMÉ
BACKGROUND: Cardiovascular disease remains one of the leading causes of death globally. Myocardial ischemia and infarction, in particular, frequently cause disturbances in cardiac electrical activity that can trigger ventricular arrhythmias. We aimed to investigate whether catestatin, an endogenous catecholamine-inhibiting peptide, ameliorates myocardial ischemia-induced ventricular arrhythmias in rats and the underlying ionic mechanisms. METHODS AND RESULTS: Adult male Sprague-Dawley rats were randomly divided into control and catestatin groups. Ventricular arrhythmias were induced by ligation of the left anterior descending coronary artery and electrical stimulation. Action potential, transient outward potassium current, delayed rectifier potassium current, inward rectifying potassium current, and L-type calcium current (ICa-L) of rat ventricular myocytes were recorded using a patch-clamp technique. Catestatin notably reduced ventricular arrhythmia caused by myocardial ischemia/reperfusion and electrical stimulation of rats. In ventricular myocytes, catestatin markedly shortened the action potential duration of ventricular myocytes, which was counteracted by potassium channel antagonists TEACl and 4-AP, and ICa-L current channel agonist Bay K8644. In addition, catestatin significantly increased transient outward potassium current, delayed rectifier potassium current, and inward rectifying potassium current density in a concentration-dependent manner. Catestatin accelerated the activation and decelerated the inactivation of the transient outward potassium current channel. Furthermore, catestatin decreased ICa-L current density in a concentration-dependent manner. Catestatin also accelerated the inactivation of the ICa-L channel and slowed down the recovery of ICa-L from inactivation. CONCLUSIONS: Catestatin enhances the activity of transient outward potassium current, delayed rectifier potassium current, and inward rectifying potassium current, while suppressing the ICa-L in ventricular myocytes, leading to shortened action potential duration and ultimately reducing the ventricular arrhythmia in rats.
Sujet(s)
Potentiels d'action , Chromogranine A , Myocytes cardiaques , Fragments peptidiques , Rat Sprague-Dawley , Animaux , Mâle , Myocytes cardiaques/effets des médicaments et des substances chimiques , Myocytes cardiaques/métabolisme , Chromogranine A/pharmacologie , Chromogranine A/métabolisme , Potentiels d'action/effets des médicaments et des substances chimiques , Fragments peptidiques/pharmacologie , Canaux calciques de type L/métabolisme , Canaux calciques de type L/effets des médicaments et des substances chimiques , Troubles du rythme cardiaque/physiopathologie , Troubles du rythme cardiaque/prévention et contrôle , Troubles du rythme cardiaque/métabolisme , Antiarythmiques/pharmacologie , Ventricules cardiaques/effets des médicaments et des substances chimiques , Ventricules cardiaques/métabolisme , Ventricules cardiaques/physiopathologie , Canaux potassiques rectifiants entrants/métabolisme , Canaux potassiques rectifiants entrants/effets des médicaments et des substances chimiques , Modèles animaux de maladie humaine , Inhibiteurs des canaux potassiques/pharmacologie , Rats , Techniques de patch-clamp , Canaux potassiques rectifiants retardés/métabolisme , Canaux potassiques rectifiants retardés/effets des médicaments et des substances chimiques , Canaux potassiques/métabolisme , Canaux potassiques/effets des médicaments et des substances chimiquesRÉSUMÉ
Heart failure (HF) with reduced ejection fraction (HFrEF) is a risk factor for drug-induced QT interval prolongation. It is unknown if HF with preserved ejection fraction (HFpEF) is also associated with an increased risk. Dofetilide and sotalol are potent QT interval-prolonging agents that are frequently used in patients with HFpEF, in whom atrial fibrillation is a common comorbidity. We tested the hypothesis that the risk of QT interval prolongation associated with dofetilide and sotalol is increased in patients with HFpEF. We conducted a retrospective cohort study conducted using electronic health records from the Indiana Network for Patient Care (January 31, 2010 -May 3, 2021). After removing patients with overlapping diagnoses of HFpEF and HFrEF, no diagnosis code, and absence of QT interval records, we identified patients taking dofetilide or sotalol among three groups: HFrEF (n = 138), HFpEF (n = 109), and no HF (n = 729). QT prolongation was defined as heart rate-corrected QT (QTc) > 500 ms during dofetilide/sotalol therapy. Unadjusted odds ratios (OR) for QT prolongation were determined by univariate analysis. Adjusted ORs were determined by generalized estimating equations (GEE) with logit link to account for an individual cluster with different times of hospitalization and covariates. QTc prolongation associated with dofetilide or sotalol occurred in 53.2%, 71.7% and 30.0% of patients with HFpEF, HFrEF, and patients with no HF, respectively. After adjusting for age, sex, race, serum potassium and magnesium concentrations, kidney function, concomitant drug therapy, and comorbid conditions, the adjusted odds of QTc prolongation were significantly higher in patients with HFpEF [OR = 1.98 (95% CI 1.17-3.33)], and in those with HFrEF [OR = 5.23, (3.15-8.67)], compared to those with no evidence of HF. The odds of QT prolongation among inpatients receiving dofetilide or sotalol were increased in patients with HFpEF and HFrEF compared to those who did not have HF.
Sujet(s)
Défaillance cardiaque , Syndrome du QT long , Phénéthylamines , Sotalol , Débit systolique , Sulfonamides , Humains , Défaillance cardiaque/physiopathologie , Défaillance cardiaque/traitement médicamenteux , Femelle , Mâle , Sujet âgé , Phénéthylamines/effets indésirables , Sotalol/effets indésirables , Débit systolique/effets des médicaments et des substances chimiques , Études rétrospectives , Sulfonamides/effets indésirables , Syndrome du QT long/induit chimiquement , Syndrome du QT long/physiopathologie , Syndrome du QT long/épidémiologie , Adulte d'âge moyen , Sujet âgé de 80 ans ou plus , Électrocardiographie , Antiarythmiques/effets indésirables , Facteurs de risqueRÉSUMÉ
AIMS: Catheter ablation (CA) is a well-established treatment option for atrial fibrillation (AF), where sedation and analgesia are pivotal for patient comfort and lesion formation. The impact of anaesthesia type on AF recurrence rates remains uncertain. This study aimed to examine AF recurrence rates depending on conscious sedation (CS) vs. general anaesthesia (GA) during CA. METHODS AND RESULTS: Utilizing nationwide data from the Danish healthcare registries, we conducted this cohort study involving adults (≥18 years) undergoing first-time CA for AF between 2010 and 2018. Patients were categorized by anaesthesia type (CS or GA), with the primary endpoint being AF recurrence, defined by a composite endpoint of either antiarrhythmic drug (AAD) prescriptions, AF-related hospital admissions, electrical cardioversions, or AF re-ablation. The impact of anaesthesia type was evaluated using multivariable Cox proportional hazards analysis. The study cohort comprised 7957 (6421 CS and 1536 GA) patients. Persistent AF, hypertension, and heart failure, as well as use of AAD, were more prevalent in the GA group. Cumulative incidences of recurrent AF were higher in the CS group at 1 (46% vs. 37%) and at 5 (68% vs. 63%) years. Multivariate analysis revealed CS as significantly associated with increased risk of AF recurrence at 5-year follow-up [hazard ratio 1.26 (95% confidence interval 1.15-1.38)], consistent across paroxysmal and persistent AF subtypes. CONCLUSION: This nationwide cohort study suggests a higher risk of AF recurrence with CS during CA compared to GA. These results advocate for considering GA as the preferred anaesthesia type for improved CA outcomes.
Sujet(s)
Anesthésie générale , Fibrillation auriculaire , Ablation par cathéter , Sédation consciente , Récidive , Enregistrements , Humains , Fibrillation auriculaire/chirurgie , Fibrillation auriculaire/épidémiologie , Mâle , Femelle , Danemark/épidémiologie , Anesthésie générale/statistiques et données numériques , Adulte d'âge moyen , Ablation par cathéter/statistiques et données numériques , Sédation consciente/statistiques et données numériques , Sujet âgé , Résultat thérapeutique , Facteurs de risque , Antiarythmiques/usage thérapeutiqueRÉSUMÉ
BACKGROUND: There are no randomized studies comparing the maintenance of sinus rhythm after catheter ablation (CA) concerning treatment with antiarrhythmic drugs (AA) in elderly patients with paroxysmal atrial fibrillation (AF). OBJECTIVES: To compare the clinical results of pulmonary vein (PV) isolation with the second-generation PVAC Gold catheter against AA treatment in elderly people with recurrent symptomatic paroxysmal AF, refractory to at least one AA, and without structural heart disease. METHODS: Sixty patients with paroxysmal AF ≥ 65 years old were randomized to two forms of treatment: group 1: CA and group 2: AA drugs. The primary outcome was the AF recurrence-free rate after at least one year of follow-up. Secondary outcomes were: progression to persistent forms of AF, impact on quality of life (QOLF), and complications. The significance level adopted in the statistical analysis was 5% (p<0.05). RESULTS: The AF recurrence-free rate was 80% (10% with amiodarone) in the CA group, after 1.3 procedures per patient and 65% in the AA group (60% with amiodarone), (p = 0.119) in an average follow-up of 719 days (Q1: 566; Q3: 730). The persistent AF free rate was 83.4% in the AC group and 67.7% in the AA group (p = 0.073) Both strategies showed an improvement in the AFQoL score during follow-up (p < 0.001), with no difference between the groups. Although without clinical repercussions or impact on the intellectual assessment test, 25% of patients in the CA group showed signs of cerebral embolization on brain MRI. CONCLUSIONS: Both strategies for maintaining sinus rhythm promoted an improvement in the quality of life of elderly patients with symptomatic AF, with no statistical difference in the clinical outcomes. Additional studies using technologies with a better safety profile are needed to evaluate the benefits of CA in elderly patients with AF.
FUNDAMENTO: Não existem estudos randomizados comparando a manutenção do ritmo sinusal após ablação por cateter (AC) em relação ao tratamento com fármacos antiarrítmicos (AA) em pacientes idosos portadores fibrilação atrial (FA) paroxística. OBJETIVOS: Comparar os resultados clínicos do isolamento das veias pulmonares (VPs) com o cateter PVAC Gold de segunda geração com o uso de AA em idosos com FA paroxística sintomática, recorrente, apesar do uso de fármacos AA. MÉTODOS: Sessenta pacientes com FA paroxística ≥ 65 anos e sem cardiopatias estruturais foram randomizados para duas formas de tratamento: grupo 1: AC e grupo 2: AA. O desfecho primário foi a taxa livre de recorrência de FA após pelo menos um ano de seguimento. Os desfechos secundários foram: progressão para formas persistentes de FA, impacto na qualidade de vida (QVFA) e complicações. O nível de significância adotado na análise estatística foi de 5% (p<0,05). RESULTADOS: A taxa livre de recorrência de FA foi de 80% (10% com amiodarona) no grupo AC, após 1,3 procedimentos por paciente e de 65% no grupo AA (60% com amiodarona), (p = 0,119) num seguimento médio de 719 dias (Q1: 566; Q3: 730). A taxa livre de FA persistente foi de 83,4% no grupo AC e de 67,7% no grupo AA (p = 0,073). Ambas as estratégias apresentaram melhora no escore de QVFA durante o seguimento (p < 0,001), sem diferença entre os grupos. Embora sem repercussão clínica ou impacto no teste de avaliação intelectual, 25% dos pacientes do grupo PVAC apresentou sinais de embolização cerebral na RNM cerebral. CONCLUSÕES: Ambas as estratégias para manutenção do ritmo sinusal promoveram melhora na qualidade de vida de pacientes idosos com FA sintomática, sem diferença estatística nos desfechos clínicos preconizados. Estudos adicionais usando tecnologias com melhor perfil de segurança são necessários para avaliar os benefícios da AC em pacientes idosos com FA.
Sujet(s)
Antiarythmiques , Fibrillation auriculaire , Ablation par cathéter , Veines pulmonaires , Qualité de vie , Humains , Fibrillation auriculaire/chirurgie , Fibrillation auriculaire/traitement médicamenteux , Fibrillation auriculaire/thérapie , Fibrillation auriculaire/physiopathologie , Antiarythmiques/usage thérapeutique , Femelle , Mâle , Sujet âgé , Ablation par cathéter/méthodes , Résultat thérapeutique , Veines pulmonaires/chirurgie , Récidive , Amiodarone/usage thérapeutique , Facteurs tempsRÉSUMÉ
The pro- and antiarrhythmic effects of omega-3 polyunsaturated fatty acids (n-3 PUFAs) have been extensively studied in preclinical and human trials. Despite early evidence of an antiarrhythmic role of n-3 PUFA in the prevention of sudden cardiac death and postoperative and persistent atrial fibrillation (AF), subsequent well-designed randomized trials have largely not shown an antiarrhythmic benefit. Two trials that tested moderate and high-dose n-3 PUFA demonstrated a reduction in sudden cardiac death, but these findings have not been widely replicated, and the potential of eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) to reduce arrhythmic death in combination, or as monotherapy, remains uncertain. The accumulated clinical evidence does not support supplementation of n-3 PUFA for postoperative AF or secondary prevention of AF. Several large, contemporary, randomized controlled trials of high-dose n-3 PUFA for primary or secondary cardiovascular prevention have demonstrated a small, significant, dose-dependent increased risk of incident AF compared with mineral oil or corn oil comparator. These findings were reproduced with both icosapent ethyl monotherapy and a mixed EPA+DHA formulation. The proarrhythmic mechanism of increased AF in contemporary cohorts exposed to high-dose n-3 PUFA is unknown. EPA and DHA and their metabolites have pleiotropic cardiometabolic and pro- and antiarrhythmic effects, including modification of the lipid raft microenvironment; alteration of cell membrane structure and fluidity; modulation of sodium, potassium, and calcium currents; and regulation of gene transcription, cell proliferation, and inflammation. Further characterization of the complex association between EPA, EPA+DHA, and DHA and AF is needed. Which formulations, dose ranges, and patient subgroups are at highest risk, remain unclear.
Sujet(s)
Troubles du rythme cardiaque , Acides gras omega-3 , Humains , Acides gras omega-3/usage thérapeutique , Troubles du rythme cardiaque/prévention et contrôle , Animaux , Fibrillation auriculaire/prévention et contrôle , Fibrillation auriculaire/traitement médicamenteux , Mort subite cardiaque/prévention et contrôle , Mort subite cardiaque/étiologie , Antiarythmiques/usage thérapeutique , Compléments alimentaires , Acide eicosapentanoïque/analogues et dérivés , Acide eicosapentanoïque/usage thérapeutique , Essais contrôlés randomisés comme sujet , Acide docosahexaénoïque/usage thérapeutiqueRÉSUMÉ
Digoxin, the oldest known cardiovascular drug, is still used today to treat heart failure and atrial fibrillation. Because it has a narrow therapeutic index and multiple interactions, it frequently causes toxicity with a wide range of symptoms and cardiac arrhythmias. More importantly, elevated serum digoxin levels have been linked to a higher risk of death in patients with heart failure or atrial fibrillation, even without signs or symptoms of toxicity. This article reviews the current state of digoxin use, its pharmacologic principles, and the mechanisms, clinical presentation, and management of toxicity.
Sujet(s)
Fibrillation auriculaire , Digoxine , Défaillance cardiaque , Digoxine/effets indésirables , Digoxine/sang , Humains , Fibrillation auriculaire/traitement médicamenteux , Défaillance cardiaque/induit chimiquement , Cardiotoniques/usage thérapeutique , Cardiotoniques/effets indésirables , Cardiotoniques/pharmacologie , Antiarythmiques/effets indésirablesRÉSUMÉ
Sodium-glucose cotransporter type 2 inhibitors (SGLT2i) were initially recommended as oral anti-diabetic drugs to treat type 2 diabetes (T2D), by inhibiting SGLT2 in proximal tubule and reduce renal reabsorption of sodium and glucose. While many clinical trials demonstrated the tremendous potential of SGLT2i for cardiovascular diseases. 2022 AHA/ACC/HFSA guideline first emphasized that SGLT2i were the only drug class that can cover the entire management of heart failure (HF) from prevention to treatment. Subsequently, the antiarrhythmic properties of SGLT2i have also attracted attention. Although there are currently no prospective studies specifically on the anti-arrhythmic effects of SGLT2i. We provide clues from clinical and fundamental researches to identify its antiarrhythmic effects, reviewing the evidences and mechanism for the SGLT2i antiarrhythmic effects and establishing a novel paradigm involving intracellular sodium, metabolism and autophagy to investigate the potential mechanisms of SGLT2i in mitigating arrhythmias.
Sujet(s)
Antiarythmiques , Troubles du rythme cardiaque , Diabète de type 2 , Inhibiteurs du cotransporteur sodium-glucose de type 2 , Inhibiteurs du cotransporteur sodium-glucose de type 2/usage thérapeutique , Inhibiteurs du cotransporteur sodium-glucose de type 2/effets indésirables , Humains , Animaux , Diabète de type 2/traitement médicamenteux , Diabète de type 2/diagnostic , Antiarythmiques/usage thérapeutique , Antiarythmiques/effets indésirables , Troubles du rythme cardiaque/traitement médicamenteux , Troubles du rythme cardiaque/physiopathologie , Troubles du rythme cardiaque/prévention et contrôle , Troubles du rythme cardiaque/métabolisme , Résultat thérapeutique , Rythme cardiaque/effets des médicaments et des substances chimiques , Autophagie/effets des médicaments et des substances chimiques , Transporteur-2 sodium-glucose/métabolisme , Potentiels d'action/effets des médicaments et des substances chimiques , Sodium/métabolismeRÉSUMÉ
INTRODUCTION: Three randomised controlled trials (RCTs) have demonstrated that first-line cryoballoon pulmonary vein isolation decreases atrial tachycardia in patients with symptomatic paroxysmal atrial fibrillation (PAF) compared with antiarrhythmic drugs (AADs). The aim of this study was to develop a cost-effectiveness model (CEM) for first-line cryoablation compared with first-line AADs for the treatment of PAF. The model used a Danish healthcare perspective. METHODS: Individual patient-level data from the Cryo-FIRST, STOP AF and EARLY-AF RCTs were used to parameterise the CEM. The model structure consisted of a hybrid decision tree (one-year time horizon) and a Markov model (40-year time horizon, with a three-month cycle length). Health-related quality of life was expressed in quality-adjusted life years (QALYs). Costs and benefits were discounted at 3% per year. Model outcomes were produced using probabilistic sensitivity analysis. RESULTS: First-line cryoablation is dominant, meaning it results in lower costs (-2,663) and more QALYs (0.18) when compared to first-line AADs. First-line cryoablation also has a 99.96% probability of being cost-effective, at a cost-effectiveness threshold of 23,200 per QALY gained. Regardless of initial treatment, patients were expected to receive â¼ 1.2 ablation procedures over a lifetime horizon. CONCLUSION: First-line cryoablation is both more effective and less costly (i.e. dominant), when compared with AADs for patients with symptomatic PAF in a Danish healthcare system.
Sujet(s)
Antiarythmiques , Fibrillation auriculaire , Analyse coût-bénéfice , Cryochirurgie , Coûts des médicaments , Chaines de Markov , Modèles économiques , Qualité de vie , Années de vie ajustées sur la qualité , Essais contrôlés randomisés comme sujet , Fibrillation auriculaire/diagnostic , Fibrillation auriculaire/chirurgie , Fibrillation auriculaire/économie , Fibrillation auriculaire/thérapie , Fibrillation auriculaire/traitement médicamenteux , Fibrillation auriculaire/physiopathologie , Humains , Cryochirurgie/économie , Cryochirurgie/effets indésirables , Danemark , Antiarythmiques/usage thérapeutique , Antiarythmiques/économie , Résultat thérapeutique , Facteurs temps , Mâle , Femelle , Adulte d'âge moyen , Techniques d'aide à la décision , Sujet âgé , Veines pulmonaires/chirurgie , Veines pulmonaires/physiopathologie , Économies , Arbres de décisionRÉSUMÉ
BACKGROUND: Cardiac dysfunction, including arrhythmias, may be one of the main clinical manifestations of Becker muscular dystrophy (BMD). Amiodarone is widely used to treat arrhythmia. However, multi-systemic toxicity caused by amiodarone, especially hepatotoxicity, should not be neglected. Here, we introduce a novel case of multi-systemic amiodarone toxicity involving the liver, renal and coagulation in BDM patient with ABCB4 gene mutation. CASE PRESENTATION: We present a case of a 16-year-old boy admitted with heart failure and atrial fibrillation (AF). He was diagnosed with Becker muscular dystrophy (BMD) and gene testing showed comorbid mutations in gene DMD, ABCB4 and DSC2. Amiodarone was prescribed to control the paroxysmal atrial fibrillation intravenously. However, his liver enzyme levels were sharply elevated, along with cardiac shock, renal failure and coagulation disorders. After bedside continuous renal replacement therapy, the patient's liver function and clinical status rehabilitated. CONCLUSIONS: ABCB4 gene mutation might be involved in amiodarone-induced hepatotoxicity. Studies in a cohort might help to prove this hypothesis in the future.
Sujet(s)
Sous-famille B de transporteurs à cassette liant l'ATP , Amiodarone , Antiarythmiques , Défaillance cardiaque , Myopathie de Duchenne , Mutation , Humains , Amiodarone/effets indésirables , Amiodarone/administration et posologie , Mâle , Adolescent , Défaillance cardiaque/induit chimiquement , Sous-famille B de transporteurs à cassette liant l'ATP/génétique , Antiarythmiques/effets indésirables , Antiarythmiques/usage thérapeutique , Antiarythmiques/administration et posologie , Myopathie de Duchenne/traitement médicamenteux , Myopathie de Duchenne/génétique , Myopathie de Duchenne/complications , Lésions hépatiques dues aux substances/génétique , Lésions hépatiques dues aux substances/étiologie , Fibrillation auriculaire/traitement médicamenteuxRÉSUMÉ
OBJECTIVES: Celastrol has widespread therapeutic applications in various pathological conditions, including chronic inflammation. Previous studies have demonstrated the potent cardioprotective effects of celastrol. Nevertheless, limited attention has been given to its potential in reducing ventricular arrhythmias (VAs) following myocardial infarction (MI). Hence, this study aimed to elucidate the potential mechanisms underlying the regulatory effects of celastrol on VAs and cardiac electrophysiological parameters in rats after MI. METHODS: Sprague-Dawley rats were divided at random: the sham, MI, and MI + celastrol groups. The left coronary artery was occluded in the MI and MI + Cel groups. Electrocardiogram, heart rate variability (HRV), ventricular electrophysiological parameters analysis, histology staining of ventricles, Enzyme-linked immunosorbent assay (ELISA), western blotting and Quantitative real-time polymerase chain reaction (qRT-PCR) were performed to elucidate the underlying mechanism of celastrol. Besides, H9c2 cells were subjected to hypoxic conditions to create an in vitro model of MI and then treated with celastrol for 24â¯hours. Nigericin was used to activate the NLRP3 inflammasome. RESULTS: Compared with that MI group, cardiac electrophysiology instability was significantly alleviated in the MI + celastrol group. Additionally, celastrol improved HRV, upregulated the levels of Cx43, Kv.4.2, Kv4.3 and Cav1.2, mitigated myocardial fibrosis, and inhibited the NLRP3 inflammasome pathway. In vitro conditions also supported the regulatory effects of celastrol on the NLRP3 inflammasome pathway. CONCLUSIONS: Celastrol could alleviate the adverse effects of VAs after MI partially by promoting autonomic nerve remodeling, ventricular electrical reconstruction and ion channel remodeling, and alleviating ventricular fibrosis and inflammatory responses partly by through inhibiting the NLRP3/Caspase-1/IL-1ß pathway.
Sujet(s)
Antiarythmiques , Troubles du rythme cardiaque , Caspase-1 , Défaillance cardiaque , Interleukine-1 bêta , Infarctus du myocarde , Protéine-3 de la famille des NLR contenant un domaine pyrine , Triterpènes pentacycliques , Rat Sprague-Dawley , Transduction du signal , Animaux , Protéine-3 de la famille des NLR contenant un domaine pyrine/métabolisme , Triterpènes pentacycliques/pharmacologie , Caspase-1/métabolisme , Antiarythmiques/pharmacologie , Transduction du signal/effets des médicaments et des substances chimiques , Mâle , Rats , Interleukine-1 bêta/métabolisme , Troubles du rythme cardiaque/traitement médicamenteux , Défaillance cardiaque/traitement médicamenteux , Défaillance cardiaque/métabolisme , Défaillance cardiaque/physiopathologie , Infarctus du myocarde/traitement médicamenteux , Infarctus du myocarde/métabolisme , Infarctus du myocarde/anatomopathologie , Triterpènes/pharmacologie , Maladie chronique , Inflammasomes/métabolisme , Inflammasomes/effets des médicaments et des substances chimiques , Lignée cellulaire , Rythme cardiaque/effets des médicaments et des substances chimiques , Modèles animaux de maladie humaineRÉSUMÉ
BACKGROUND: The favorable benefits of early rhythm control (ERC) therapy in newly diagnosed patients with atrial fibrillation (AF) have been demonstrated in the EAST-AFNET 4 trial. However, the generalizability and applicability of ERC in real-world clinical settings remain inconclusive. METHODS: We conducted a systematic search of the PubMed and Embase databases to identify observational studies published between January 2020 and February 2024 that focused on real-world evidence pertaining to ERC. The effectiveness and safety outcomes in our study were analogous to those evaluated in the EAST-AFNET 4 trial. RESULTS: A total of 4 observational studies that fulfilled the inclusion criteria of EAST-AFNET 4 were included, involving 130,970 patients with AF, 30.7% of whom received ERC therapy. In our pooled analysis using the fixed-effects model, compared with rate control, ERC significantly decreased the occurrence risk of the primary composite outcome (hazard ratio [HR] 0.86, 95% confidence interval[CI] 0.82-0.91), cardiovascular death (HR 0.87, 95% CI 0.78-0.98), stroke (HR 0.80, 95% CI 0.73-0.87), and hospitalization with worsening heart failure (HR 0.91, 95% CI 0.84-0.99) or acute coronary syndrome (HR 0.72, 95% CI 0.59-0.87). In terms of safety outcomes, there were no differences in the composite safety outcome (HR 1.00, 95% CI 0.95-1.05) and all-cause death (HR 0.93, 95% CI 0.82-1.06) between the two studied groups. CONCLUSIONS: ERC therapy showed favorable effectiveness outcomes compared with rate control, whereas the safety outcomes between the two therapeutic strategies did not differ significantly, supporting the benefits of ERC therapy over rate control in selected real-world patients with AF. REGISTRATION: The study protocol was registered to PROSPERO (CRD42023443569).
Sujet(s)
Fibrillation auriculaire , Fibrillation auriculaire/physiopathologie , Fibrillation auriculaire/thérapie , Fibrillation auriculaire/diagnostic , Humains , Rythme cardiaque/physiologie , Antiarythmiques/usage thérapeutique , Études observationnelles comme sujet/méthodes , Résultat thérapeutiqueRÉSUMÉ
Amiodarone and mexiletine are used for ventricular arrhythmias, for which a combination therapy of both anti-arrhythmic drugs (AADs) is not uncommon. Therapeutic drug monitoring (TDM) can be beneficial for clinical guidance of therapy, especially to correctly identify adverse events. Desethylamiodarone, the active metabolite of amiodarone, accumulates over time and is associated with serious adverse events. Therefore, simultaneous TDM for amiodarone, desethylamiodarone and mexiletine is advantageous in clinical practice. The presented LC-MS/MS method was validated for selectivity, matrix effect, linearity, accuracy, precision, carry-over and stability. The method was continuously evaluated during eight months of clinical use. The method was shown to be linear within the measured range of 0.1 to 10 mg/L for each component. The matrix effect was considered negligible. No interfering responses were found for amiodarone, desethylamiodarone and the isotopic-labeled internal standards. A constant and reproducible within-run contribution of 45.3 %, originating from the system, was identified for mexiletine. The systemic contribution to the peak area of the lowest quantifiable concentration of mexiletine affected the selectivity and carry-over effect measurements. Multiple measurements showed that regression adjusted concentrations were accurate and reproducible, indicating calibration correction was applicable. Sample stability was found to be within limits for all storage conditions and freeze-thaw cycles. Furthermore, long-term method evaluation with external controls resulted in stable measurements with a percentage coefficient of variance between 1.3 % and 6.3 %. The presented practical and reliable method is applicable for clinical TDM and will allow clinical practitioners to guide drug therapy of amiodarone and mexiletine.
Sujet(s)
Amiodarone , Méxilétine , Spectrométrie de masse en tandem , Amiodarone/sang , Amiodarone/analogues et dérivés , Humains , Spectrométrie de masse en tandem/méthodes , Méxilétine/sang , Méxilétine/analogues et dérivés , Méxilétine/composition chimique , Reproductibilité des résultats , Chromatographie en phase liquide/méthodes , Modèles linéaires , Surveillance des médicaments/méthodes , Antiarythmiques/sang , Antiarythmiques/pharmacocinétique , Limite de détection , Stabilité de médicament , Sensibilité et spécificitéRÉSUMÉ
Postoperative atrial fibrillation (POAF) is a common complication following cardiac surgery, which often occurs within 30 postoperative days, especially peaking at 2-3 days. Antiarrhythmic medications such as amiodarone are recommended in clinical practice for the prophylaxis and treatment of POAF. However, conventional oral administration is hindered due to delayed drug action and high risks of systemic toxicity, and emerging localized delivery strategies suffer from a limited release duration (less than 30 days). Herein, we develop a microneedle (MN) patch for localized delivery of amiodarone to the atria in a "First Rapid and Then Sustained" dual-release mode. Specifically, this patch is composed of a needle array integrated with an amiodarone-loaded reservoir for a sustained and steady release for over 30 days; and an amiodarone-containing coating film deposited on the needle surface via the Langmuir-Blodgett technique for a rapid release at the first day. Upon this design, only one MN patch enables a higher drug accumulation in the atrial tissue at the first day than oral administration and simultaneously remains therapeutical levels for over 30 days, despite at a significantly reduced drug dosage (5.08 mg in total versus â¼10 mg per day), thereby achieving ideal preventive effects and safety in a rat model. Our findings indicate that this MN device provides a robust and efficient delivery platform for long-term prophylaxis of POAF.
Sujet(s)
Fibrillation auriculaire , Aiguilles , Fibrillation auriculaire/prévention et contrôle , Fibrillation auriculaire/traitement médicamenteux , Animaux , Rats , Rat Sprague-Dawley , Amiodarone/administration et posologie , Amiodarone/composition chimique , Antiarythmiques/administration et posologie , Antiarythmiques/composition chimique , Antiarythmiques/pharmacologie , Mâle , Systèmes de délivrance de médicaments , Complications postopératoires/prévention et contrôleRÉSUMÉ
Cardiac arrhythmias cause a significant proportion of hospitalizations and physician contacts worldwide. By using antiarrhythmic drugs, cardiac arrhythmias can be effectively treated and the frequency of recurrences reduced. Atrial fibrillation and heart failure represent diseases in which antiarrhythmic drugs are more often used on a long-term basis. The aim of this article is to provide an overview of the most common antiarrhythmic drugs and their uses as well as to provide recommendations for adequate handling and use, especially in the outpatient setting. In addition to long-term use, some antiarrhythmic drugs are also administered for the acute management of supraventricular or ventricular tachycardia. Relevant contraindications, side effects and interactions must be considered, meaning that patients should be followed up when using these potent drugs. This article shows in detail what to consider when using antiarrhythmic drugs in order to ensure not only effective but also safe treatment.
Sujet(s)
Antiarythmiques , Troubles du rythme cardiaque , Humains , Antiarythmiques/usage thérapeutique , Antiarythmiques/effets indésirables , Troubles du rythme cardiaque/traitement médicamenteux , Troubles du rythme cardiaque/induit chimiquement , Fibrillation auriculaire/traitement médicamenteux , Défaillance cardiaque/traitement médicamenteux , Tachycardie ventriculaire/traitement médicamenteux , Interactions médicamenteuses , Tachycardie supraventriculaire/traitement médicamenteuxRÉSUMÉ
OBJECTIVE: High plasma levels of mono-N-desethylamiodarone (MDEA), an active amiodarone metabolite, may be associated with tissue toxicity in heart failure (patients with heart rhythm disturbances); therefore, a tool that can identify patients for whom therapeutic drug monitoring (TDM) of MDEA is required. This multicenter study aimed to develop a decision tree (DT) model that can identify patients with heart rhythm disturbances at high MDEA concentrations. MATERIALS AND METHODS: A multicenter retrospective cohort study was conducted, including 157 adult patients with heart failure who received oral amiodarone treatment. A χ2 automatic interaction-detection algorithm was used to construct a DT model. In the DT analysis, the dependent variable was set as an MDEA trough plasma concentration of ≥ 0.6 µg/mL during the steady-state period. Explanatory variables were selected as factors with p < 0.05 in multivariate logistic regression analysis. RESULTS: The adjusted odds ratios for the daily dose of amiodarone and body mass index were 1.01 (95% coefficient interval: 1.008 - 1.021, p < 0.001) and 0.91 (95% confidence interval: 0.834 - 0.988, p = 0.025), respectively. For DT analysis, the risk of reaching plasma MDEA concentrations ≥ 0.6 µg/mL was relatively high, combined with a daily dose of amiodarone > 100 mg and body mass index ≤ 22.3 kg/m2 at 69.0% (20/29), and its trend was also detected in the sensitivity analysis. CONCLUSION: Patients taking a daily amiodarone dose > 100 mg and with a body mass index ≤ 22.3 kg/m2 warrant TDM implementation for MDEA to minimize the risk of MDEA-induced tissue toxicity.
Sujet(s)
Amiodarone , Antiarythmiques , Arbres de décision , Surveillance des médicaments , Humains , Amiodarone/effets indésirables , Amiodarone/administration et posologie , Amiodarone/pharmacocinétique , Amiodarone/analogues et dérivés , Études rétrospectives , Mâle , Femelle , Sujet âgé , Antiarythmiques/effets indésirables , Antiarythmiques/administration et posologie , Antiarythmiques/pharmacocinétique , Antiarythmiques/sang , Adulte d'âge moyen , Surveillance des médicaments/méthodes , Défaillance cardiaque/traitement médicamenteux , Sujet âgé de 80 ans ou plusRÉSUMÉ
Atrial fibrillation and heart failure are among the most common cardiovascular diseases and have a significant impact on the mortality and morbidity of affected patients. From a pathophysiological perspective, the two diseases are closely related and often perpetuate each other. Therefore, effective management of atrial fibrillation is now a central component of modern heart failure treatment. Based on current data, sinus rhythm should primarily be permanently maintained in patients with systolic heart failure. Catheter ablation has recently proven to be advantageous over purely pharmacological therapy and is therefore the treatment of choice for many patients with heart failure and atrial fibrillation. In patients with diastolic heart failure (heart failure with preserved ejection fraction [HFpEF]), the effect of catheter ablation is less clear. Data from randomized studies are urgently needed in order to further assess efficacy in this population.
Sujet(s)
Fibrillation auriculaire , Ablation par cathéter , Défaillance cardiaque , Fibrillation auriculaire/physiopathologie , Fibrillation auriculaire/thérapie , Humains , Défaillance cardiaque/physiopathologie , Ablation par cathéter/méthodes , Antiarythmiques/usage thérapeutiqueRÉSUMÉ
We studied the effect of Refralon on the electrophysiological properties of the supraventricular myocardium against the background of adrenergic (epinephrine) influence in the zone of the pulmonary veins, the area where 50-90% of atrial arrhythmias is triggered. The experiments were carried out on isolated tissue preparations of Wistar rats. The multichannel microelectrode array technique was used to record action potentials simultaneously in the atrium and in the ostium and distal parts of the pulmonary veins. Epinephrine application (12-50 nM) led to depolarization of the resting potential and the conduction block in the distal part of the pulmonary veins. Refralon (30 µg/kg) restored the resting potential in the distal part of the pulmonary veins. Against the background of epinephrine, Refralon did not significantly change the duration of the action potential at 90% repolarization in comparison with control. At the same time, the comparison drug E-4031 against the background of epinephrine significantly increased the duration of action potential in the atrium and in the ostium of the pulmonary veins, and sotalol increased it only in the ostium. Neither E-4031, nor sotalol restored conduction in their distal part. Refralon has a biphasic effect under conditions of adrenergic stimulation: the fast component is responsible for stabilizing the resting potential in the pulmonary vein and reduces the dispersion of action potential duration in the atrium and pulmonary vein and is also quickly washed away, and the slow component is responsible for the increase of the action potential duration and is slowly washed away.
Sujet(s)
Potentiels d'action , Antiarythmiques , Épinéphrine , Atrium du coeur , Veines pulmonaires , Rat Wistar , Animaux , Rats , Épinéphrine/pharmacologie , Potentiels d'action/effets des médicaments et des substances chimiques , Antiarythmiques/pharmacologie , Veines pulmonaires/effets des médicaments et des substances chimiques , Mâle , Atrium du coeur/effets des médicaments et des substances chimiques , Atrium du coeur/physiopathologie , Troubles du rythme cardiaque/physiopathologie , Troubles du rythme cardiaque/traitement médicamenteuxRÉSUMÉ
Left ventricular assist devices (LVADs) are widely used as end-stage therapy in patients with advanced heart failure, whereas implantation increases the risks of development of sustained ventricular tachycardia at the later postimplantation stage. Therefore, this study aimed to evaluate the clinical efficacy of orally administered amiodarone and propranolol in 3 patients with ventricular tachycardia (VT) after LVAD implantation who were resistant to initial anti-antiarrhythmic drugs. This retrospective cohort study consisted of the initial evaluation of the clinical data of 14 adult patients who underwent implantation of LVAD between January 2019 and March 2021. A total of 3 patients with resistant VT were finally included. In all cases, the patients were initially administered amiodarone in the different doses intravenously to stabilize the critical condition, whereas its oral form along with that of propranolol was used as maintenance therapy in the first 2 cases. In the third case, amiodarone was withdrawn because of the risk of development of hyperthyroidism, while oral propranolol was used in the treatment. The assessment in the 16-month follow-up period after discharge did not show presence of non-sustained and sustained VT in all 3 cases. In the ventricular arrhythmia-free group, the total mortality rate within the follow-up period was 11.1â ±â 7.78 months in the 3 patients. We suggest that maintenance oral therapy of propranolol and amiodarone can significantly decrease the risks of complications in patients with VT after implantation of ventricular assist device in the long term.